Endocrine Toxicities of Antineoplastic Therapy

Giulia Puliani^{1

2}, Marialuisa Appetecchia¹

Affiliations

¹ Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
² Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.

PMID: 33466843
PMCID: PMC7830439
DOI: 10.3390/cancers13020294

Editorial

Endocrine Toxicities of Antineoplastic Therapy

Giulia Puliani et al. Cancers (Basel). 2021.

. 2021 Jan 14;13(2):294.

doi: 10.3390/cancers13020294.

Authors

Giulia Puliani^{1

2}, Marialuisa Appetecchia¹

Affiliations

¹ Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
² Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.

PMID: 33466843
PMCID: PMC7830439
DOI: 10.3390/cancers13020294

Abstract

In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Endocrine Adverse Events Induced by Cancer Treatments: The Role of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography.
Giovanella L, Tuncel M, Campennì A, Ruggeri RM, Huellner M, Petranović Ovčariček P. Giovanella L, et al. Cancers (Basel). 2025 Aug 14;17(16):2651. doi: 10.3390/cancers17162651. Cancers (Basel). 2025. PMID: 40867279 Free PMC article. Review.
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.
Raschi E, Fusaroli M, Giunchi V, Repaci A, Pelusi C, Mollica V, Massari F, Ardizzoni A, Poluzzi E, Pagotto U, Di Dalmazi G. Raschi E, et al. Cancers (Basel). 2022 Sep 22;14(19):4610. doi: 10.3390/cancers14194610. Cancers (Basel). 2022. PMID: 36230533 Free PMC article.
Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells.
Zhu Z, Xu S, Ren J, Jiang T, Zhang C, Yan Z. Zhu Z, et al. Lipids Health Dis. 2023 Aug 23;22(1):134. doi: 10.1186/s12944-023-01907-y. Lipids Health Dis. 2023. PMID: 37612751 Free PMC article.

References

1. Tang J., Shalabi A., Hubbard-Lucey V.M. Comprehensive analysis of the clinical immuno-oncology landscape. Ann. Oncol. 2018;29:84–91. doi: 10.1093/annonc/mdx755. - DOI - PubMed
1. Ruggeri R.M., Campennì A., Giuffrida G., Trimboli P., Giovanella L., Trimarchi F., Cannavò S. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know) J. Endocrinol. Investig. 2018;42:745–756. doi: 10.1007/s40618-018-0984-z. - DOI - PubMed
1. Krause D.S., Van Etten R.A. Tyrosine Kinases as Targets for Cancer Therapy. N. Engl. J. Med. 2005;353:172–187. doi: 10.1056/NEJMra044389. - DOI - PubMed
1. Gabora K., Piciu A., Bădulescu I.C., Larg M.I., Stoian I.-A., Piciu D. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors. Drug Metab. Rev. 2019;51:562–569. doi: 10.1080/03602532.2019.1687512. - DOI - PubMed
1. Lodish M.B. Clinical review: Kinase inhibitors: Adverse effects related to the endocrine system. J. Clin. Endocrinol. Metab. 2013;98:1333–1342. doi: 10.1210/jc.2012-4085. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Endocrine Toxicities of Antineoplastic Therapy

Affiliations

Endocrine Toxicities of Antineoplastic Therapy

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources